Saturday 17 October 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 61.5% and free cash flow fell 92.6%, each against the same quarter a year earlier.
63.62
1.65
−2.53%
Follow PCVX
Vaxcyte, Inc. (PCVX) P/E ratio
Vaxcyte, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| PCVX Vaxcyte, Inc. | n/m |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| TECH Bio-Techne Corp compare | 62.0× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| BMRN BioMarin Pharmaceutical Inc. compare | 144× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)